The last week of February wasn’t an ideal time for any company to launch an initial public offering, with US stock market indices trading lower on coronavirus fears, but Passage Bio Inc. took a chance with both new and existing investors to fund clinical development of its gene therapy candidates for rare monogenic central nervous system (CNS) diseases.
CEO Bruce Goldsmith told Scrip that Passage Bio briefly considered postponing its IPO until the impacts of business interruptions related...






